Regulatory Environment - Unified has no single customer or related group of customers whose banking activities would materially impact earnings capabilities[10] - Unified is required to maintain minimum levels of capital in accordance with FDIC capital adequacy guidelines, with specific capital positions detailed in the financial statements[35] - The FDIC may terminate deposit insurance if Unified engages in unsafe practices or is in an unsafe condition[33] - Unified exceeded its minimum capital requirements under applicable guidelines as of December 31, 2025[28] - The Dodd-Frank Act has imposed new rules affecting deposit insurance assessments and capital requirements for financial institutions[34] - Unified is subject to supervision and regulation by the Federal Reserve, FDIC, and Ohio Division of Financial Institutions[20] - The regulatory environment is highly competitive, with Unified facing competition from various financial institutions in its operating regions[11] - The Company is required to obtain prior approval from the Federal Reserve for significant acquisitions and control changes[24] - The implementation of Basel III accounting for capital adequacy began in March 2015, overseen by the Federal Reserve, FDIC, and OCC[36] - As of December 31, 2025, the Bank was classified as well capitalized under the prompt corrective action guidelines[37] Financial Performance - Total assets increased to $828,079 million in 2024 from $802,054 million in 2023, representing a growth of 3.1%[61] - Net interest income decreased by $597 million, from $27,424 million in 2023 to $26,827 million in 2024[63] - Total interest and dividend income rose by $3,111 million, driven by an increase in loans by $3,134 million[63] - Total interest expense increased by $3,708 million, with time deposits contributing $2,493 million to this rise[63] - The net interest spread decreased from 3.28% in 2023 to 3.01% in 2024[61] - The average yield on tax-exempt securities available for sale was 4.71% in 2024, compared to 4.82% in 2023[61] - Total interest-bearing liabilities increased to $608,613 million in 2024 from $597,737 million in 2023, marking a rise of 1.5%[61] Employee Information - Unified has 125 full-time employees, with 39 in management positions and 8 part-time employees[53] - The Company has no compensated employees, as it operates as a holding company[53] Credit Losses and Loan Concentrations - The allowance for credit losses (ACL) is based on historical loss experience and current economic conditions, with significant changes expected from period to period[70] - The company’s largest loan concentration as of December 31, 2025, includes 1st lien 1-4 family loans at $89,580 million, representing 18.2% of total loans[68] - The ratio of net charge-offs to average loans outstanding increased to 0.08% in 2025 from 0.07% in 2024 and 0.02% in 2023[78] - The total allowance for credit losses to total loans rose to 0.87% in 2025, compared to 0.82% in 2024 and 0.81% in 2023[78] - The allowance for credit losses allocated to commercial real estate loans was $2,571 million, representing 61.65% of the total allowance in 2025[79] - The ratio of nonaccrual loans to total loans increased to 0.46% in 2025 from 0.15% in 2024 and 0.10% in 2023[78] - The ratio of total allowance for credit losses to nonperforming loans decreased to 188.02% in 2025 from 508.33% in 2024 and 611.23% in 2023[78] - The ratio of installment loans net charge-off to average consumer loans was 1.93% in 2025, consistent with 2023 but down from 2.16% in 2024[78] - The allowance for credit losses allocated to residential real estate loans was $1,034 million, accounting for 18.22% of the total allowance in 2025[79] - The allowance for credit losses allocated to commercial and industrial loans was $544 million, representing 18.72% of the total allowance in 2025[79] Deposit Insurance and Claims - Unified's deposits are insured by the FDIC, which assesses premiums based on capital levels and supervisory evaluations[32] - The Federal Deposit Insurance Act prioritizes claims of depositors in the event of liquidation, ensuring they are paid before unsecured creditors[45] - Uninsured deposits increased to approximately $124.2 million in 2025, up from $110.2 million in 2024 and $89.8 million in 2023[80] - The total amount of time deposits greater than $250,000 was $41,486 thousand as of December 31, 2025[81] Government Policies - The fiscal and monetary policies of the federal government, particularly those of the Federal Reserve, significantly affect Unified's business and earnings[49] - The SEC's final Executive Compensation Clawback Rules require listed companies to implement policies to recoup bonuses if financial results are misstated, with compliance required by December 1, 2023[42] Business Operations - Ohio chartered banks can establish branches anywhere in Ohio, subject to regulatory approvals, and can also engage in interstate branching under certain conditions[43] - The Company operates solely in the banking sector, with no diversification into other business lines[57]

Supply Chain and Vendor Dependence - The company's 20 largest suppliers accounted for approximately 80% of merchandise purchased in fiscal 2026, with five suppliers (Apple, Samsung, HP, LG, and Sony) representing about 55% of total merchandise purchased [80]. - The company imports approximately 1% to 3% of its overall assortment directly, relying heavily on foreign vendor imports, particularly from China, Mexico, and Southeast Asia [59]. - The company’s reliance on key vendors subjects it to risks related to supply constraints and pricing pressures, which could affect margins [81]. - The company relies on third-party vendors for critical operations, and any disruptions in these relationships could negatively impact revenues and cost structures [94]. - Supply chain disruptions could adversely affect revenue and profitability, especially with increasing online purchases and reliance on a limited number of carriers [92]. Economic and Market Conditions - The company is highly sensitive to macroeconomic conditions, which could adversely affect consumer demand and financial results [53]. - Geopolitical tensions and trade policies may disrupt the supply chain and increase costs, impacting overall financial performance [58]. - The retail sector's competitive landscape is intensifying, with pressure from multi-channel retailers and e-commerce businesses affecting profit margins [69]. - The company faces challenges in maintaining a competitive cost structure due to rising labor costs and the need to offer competitive compensation [77]. - Catastrophic events, including natural disasters and pandemics, pose risks to operations and financial performance, potentially disrupting supply chains [63]. - The rapid pace of technological advancement and changing consumer preferences may adversely impact revenue and profitability if not managed effectively [66]. - Increased competition from AI-driven tools and platforms may challenge the company's pricing flexibility and market position [80]. Financial Performance and Guidance - In fiscal 2026, Best Buy generated $41.7 billion in revenue, a 0.4% increase from $41.5 billion in fiscal 2025, with comparable sales growing by 0.5% [178]. - Gross profit for fiscal 2026 was $9.373 billion, representing 22.5% of revenue, slightly down from 22.6% in fiscal 2025 [177]. - Operating income for fiscal 2026 was $1.389 billion, with an operating income margin of 3.3%, up from 3.0% in fiscal 2025 [177]. - Net earnings for fiscal 2026 were $1.069 billion, leading to a diluted EPS of $5.04, an increase from $4.28 in fiscal 2025 [177]. - The company’s financial performance guidance is subject to various risks and uncertainties, which could lead to a decline in stock price if not met [117]. Strategic Initiatives and Investments - The company may pursue new strategic initiatives, including acquisitions and expanding revenue streams, but these strategies carry inherent risks and uncertainties [87]. - The company launched Best Buy Marketplace in fiscal 2026, aiming to expand third-party seller count and enhance product assortment without inventory investment [171]. - Best Buy Ads is expected to grow in fiscal 2027 through existing advertisers and new opportunities, supported by investments in technology and marketing [170]. - The company plans to continue identifying cost reductions in fiscal 2027 to fund investments and offset financial pressures [172]. Store Operations and Expansion - The total number of domestic stores at the end of fiscal 2026 was 926, with a total square footage of 35,954 thousand [133]. - The total number of international stores at the end of fiscal 2026 was 142, with a total square footage of 3,575 thousand [135]. - The company plans to increase its Domestic segment Best Buy store count by approximately 4 stores by the end of fiscal 2027 [184]. - The company closed select non-traditional store locations as part of a restructuring initiative, with additional closures expected in fiscal 2027 [185]. Financial Management and Shareholder Returns - The Board approved a quarterly cash dividend increase of 1% to $0.96 per share on March 3, 2026 [147]. - During fiscal 2026, the company repurchased and retired 4.0 million shares at a cost of $273 million [149]. - The company has a share repurchase authorization of $5.0 billion with no expiration date [149]. - Cash dividends declared and paid in fiscal 2026 amounted to $801 million, a slight decrease from $807 million in fiscal 2025, despite an increase in the quarterly cash dividend per share to $3.80 [226][225]. Risks and Compliance - The company faces risks from external factors, including negative public remarks and heightened violence, which could adversely affect business operations [84]. - The company is subject to evolving corporate governance and public disclosure regulations, which may increase general and administrative expenses [112]. - The company is subject to audits by tax authorities, which may lead to adjustments in liabilities for unrecognized tax benefits based on the outcomes of these audits [245]. - The company is heavily reliant on information technology systems for key business processes, and any failures could have a material adverse impact on operations [99]. - Increasing costs associated with information security and privacy could materially affect the company's operations and financial results [108]. Performance Metrics and Adjustments - The effective tax rate decreased to 24.0% in fiscal 2026 from 28.7% in fiscal 2025, primarily due to restructuring charges [186]. - A 10% change in markdown adjustments as of January 31, 2026, would have impacted net earnings by approximately $9 million in fiscal 2026, with markdown adjustments remaining stable over the last three fiscal years [244]. - A 10% change in services membership deferred revenue as of January 31, 2026, would have affected net earnings by approximately $42 million in fiscal 2026, with deferred revenue levels stable over the last three fiscal years [250]. - The company values inventory at the lower of cost or net realizable value, with markdown adjustments reflecting excess costs over expected recovery from inventory sales [242]. - Management's estimates for markdown adjustments involve uncertainties related to historical recovery rates and consumer demand forecasts [243].

Financial Performance - 4D Molecular Therapeutics reported collaboration and license revenue of $85 million for the year ended December 31, 2025, compared to $0 million in 2024[12]. - The net loss for 2025 was $140 million, an improvement from a net loss of $161 million in 2024, resulting in a net loss per share of $2.42[14][21]. - 4DMT has $514 million in cash, cash equivalents, and marketable securities as of December 31, 2025, sufficient to fund operations into the second half of 2028[11]. - The company strengthened its balance sheet with a $118 million financing, extending its cash runway into the second half of 2028[9]. Research and Development - Research and development expenses increased to $196 million in 2025 from $141 million in 2024, primarily due to the execution of Phase 3 clinical trials for 4D-150[12]. - The company completed enrollment in the 4D-150 4FRONT-1 Phase 3 trial within approximately 11 months, with topline data expected in the first half of 2027[6]. - The target enrollment for the 4FRONT-1 and 4FRONT-2 Phase 3 trials was increased from 400 to 480 patients per trial to enhance regulatory success[9]. - 4D-150 demonstrated consistent and durable benefits in the PRISM Phase 1/2 trial, maintaining visual acuity and reducing treatment burden over 1.5-2 years of follow-up[9]. Strategic Partnerships - A strategic partnership with Otsuka Pharmaceutical was established, providing an upfront cash payment of $85 million and expected cost-sharing of at least $50 million over three years[7]. - The company is eligible for up to $336 million in potential regulatory and commercial milestones and tiered double-digit royalties from the Otsuka collaboration[8].

Financial Performance - The company has incurred net losses of $31.9 million and $32.9 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $311.7 million as of December 31, 2025[278]. - The company expects to continue incurring significant operating costs related to the development and commercialization of new tests and services, necessitating additional capital[281]. - The company may need to raise additional funds through public or private equity or debt financings to support operations and expansion[285]. - The company has federal net operating loss (NOL) carryforwards of approximately $275.8 million, with $70.3 million beginning to expire in 2028[352]. - The company may need to raise additional funds through equity or debt financing, which could dilute stockholders' ownership interests[348]. Revenue Dependence and Risks - The company relies substantially on the PreTRM test for revenue, and any failure to increase its adoption or develop new products could harm business prospects[276]. - The company derives substantially all of its revenues from the PreTRM test, and any failure to increase its adoption or develop new products could harm its business[297]. - Third-party payers currently do not reimburse for the PreTRM test, and changes in reimbursement policies could adversely affect revenue[279]. - There is substantial uncertainty regarding whether third-party payers will cover and reimburse the company's tests, which could limit revenue generation[365]. - The company faces risks related to billing disputes with third-party payers, which may lead to decreased revenue and requests for recoupment of previously paid amounts[371]. Competition and Market Challenges - The company faces intense competition in the life science industry, which could impact its ability to sustain revenue growth and achieve profitability[276]. - The company faces intense competition in the life sciences industry, with many competitors having greater financial resources and expertise in research and development[311]. - The success of the PreTRM test and future products depends on achieving broad scientific and market acceptance, which is uncertain due to various market forces[299]. Operational and Compliance Risks - The company may experience operational challenges, including supply constraints and difficulties with transportation logistics, which could impact test performance and commercial attractiveness[300][314]. - The company operates a CLIA-certified laboratory facility in Salt Lake City, which is critical for processing tests; any operational failure could significantly harm its business[315]. - The company must comply with federal and state laboratory licensing requirements, including CLIA regulations, to maintain its ability to perform tests and bill for them[398]. - Failure to maintain CLIA certification could lead to significant sanctions, including revocation of certification, adversely affecting business operations[400]. - The company is subject to risks associated with international operations, including changes in foreign laws and potential tariffs that could adversely affect cost of goods sold and market access[344]. Regulatory and Legal Compliance - The company is subject to evolving privacy laws, which could complicate compliance and increase operational risks[419]. - The company must navigate complex compliance issues arising from various federal and state laws governing patient health information, which could lead to increased litigation risks[422]. - The company may face enforcement actions from the FTC or state agencies regarding promotional materials, which could adversely affect its business[413]. - The company is subject to significant penalties and liabilities if it fails to comply with laws and regulations related to claims submission[373]. Intellectual Property and Technology Risks - The company's ability to protect its proprietary technology and brand is heavily reliant on obtaining, maintaining, and enforcing intellectual property rights[456]. - There is uncertainty regarding the patent positions of diagnostic companies, which may adversely affect the company's competitive ability in the market[456]. - The company may face challenges in patent validity and enforceability, which could lead to increased competition and negatively affect its business and financial condition[458]. - The company may not be aware of all third-party intellectual property rights that could relate to its tests or technology, leading to potential legal disputes[459]. Customer Concentration and Market Strategy - The company is subject to customer concentration risk, relying on a limited number of direct customers for a significant portion of its revenue[276]. - A significant portion of the company's revenue is expected to come from a limited number of direct customers, including Elevance Health, exposing it to customer concentration risk[303]. - The company is evaluating international expansion, with an initial focus on Europe, to increase its market presence[297]. Data Privacy and Cybersecurity - Security breaches could compromise sensitive information, including personal health information (PHI), leading to legal claims and financial penalties[429][430]. - Cybersecurity incidents could disrupt operations, affecting the company's ability to provide services and manage administrative functions, which may harm its reputation[431]. - The company relies on third-party service providers for critical business systems, and any cybersecurity incidents at these providers could have adverse consequences[441]. Economic and Market Conditions - The company’s financial condition may be adversely affected by external factors such as inflation and unstable economic conditions[277]. - Changes in the macroeconomic environment, including inflation and geopolitical conditions, could adversely impact the company's operating results[355]. - Public health threats, such as pandemics, could materially affect the company's operations and those of its third-party partners[350].

Financial Performance - As of December 31, 2025, the company generated approximately $614.9 million in revenue, a 7.1% increase from $573.7 million in 2024, with a net income of $4.7 million and an Adjusted EBITDA of $56.4 million[29]. - For the years ended December 31, 2025 and 2024, the company generated revenue of approximately $614.9 million and $573.7 million, respectively, with gross profit of $113.3 million and $81.5 million[57]. - The company’s gross profit margin for the year ended December 31, 2025, was 17.2%, an increase from 15.9% in 2024[29]. - The company has experienced seasonality in revenue, with lower activity in the fourth quarter due to public holidays[93]. - The company has successfully managed inflationary cost increases through pricing, productivity, and cost-cutting initiatives[93]. User Transactions and Growth - The company completed over 4.0 million user transactions from inception in July 2016 to December 31, 2025, totaling approximately $3.4 billion in transaction value[29]. - The company has an average of approximately 16,602 new users per quarter, defined as users completing their first transaction during that period[29]. - Bitcoin represents 99% of the total transaction volume for the year ended December 31, 2025[477]. - The company has launched BDCheckout, which allows users to load cash into their accounts at retail locations, diversifying revenue streams and increasing transaction volumes[59]. Market Presence and Expansion - The company operates approximately 9,700 kiosks across 48 U.S. states, 10 Canadian provinces, 6 Australian states, and Hong Kong, addressing approximately 69% of the U.S. population[30][49]. - The company holds a market share of approximately 23% in North America as of December 31, 2025, making it the largest BTM operator in the region[49]. - The total number of BTMs deployed globally grew from approximately 1,000 to 40,000 from January 1, 2017, to December 31, 2025, representing a CAGR of approximately 42%[43]. - The company has signed a master placement agreement with EG America LLC to install BTMs in approximately 900+ locations, marking a significant expansion[60]. - The company intends to expand into the state of New York, estimating the market could support thousands of kiosks based on comparisons with other states[56]. - The company completed the acquisition of Instant Coin Bank, further consolidating its presence in Texas and Oklahoma, reinforcing its leading market position[64]. Compliance and Regulatory Environment - The company has invested in robust compliance procedures, requiring customer identification for transactions, making it one of the few operators in the industry to implement such standards[52]. - The company is subject to various anti-money laundering laws and has implemented a compliance program to prevent illicit activities[94]. - Arizona's new Cryptocurrency Kiosk License Fraud Prevention law mandates a 10-day introductory period for new customers and daily transaction limits of $2,000 for new customers[103]. - Arkansas's Money Transmission Kiosk Act requires a fee cap of the greater of $5 or 18% and daily transaction limits of $2,000 for new customers[104]. - California's Digital Financial Assets Law limits charges to the greater of $5 or 15% of the transaction amount and requires written disclosures prior to transactions[106]. - Connecticut's Act Concerning Digital Assets imposes a transaction limit of $2,000 for new customers and caps fees at 15%[111]. - Illinois SB 2319 mandates a fee cap of 18% and daily transaction limits of $2,500 for new customers and $10,500 for existing customers[113]. - Iowa Code § 533C.1004 imposes a fee cap of the greater of $5 or 15% and a daily transaction limit of $1,000 for all customers, with an aggregate limit of $10,000 for new customers in their first 30 days[114]. - Louisiana H 483 requires a daily transaction limit of $3,000 and a 72-hour delay in transaction processing, allowing full refunds within this period without proof of fraud[115]. - Maine's legislation mandates a fee cap of the greater of $5 or 3% and a daily transaction limit of $1,000, with full refunds for fraudulent transactions within 90 days of the first kiosk transaction[116]. - Maryland S 305 establishes daily transaction limits of $2,000 for new customers and $10,500 for existing customers, with mandatory refunds for verified fraudulent transactions[117][118]. - Nebraska's LB 609 sets a transaction limit of $2,000 for new customers and $10,500 for existing customers, with an 18% fee cap and full refunds for new customers within their first 14 days[121]. - North Dakota H 1447 requires a daily transaction limit of $2,000 for all customers, focusing on record-keeping through mandatory receipts[122][123]. - Oklahoma S 1083 imposes a fee cap of 15% and a daily transaction limit of $2,000 for new customers, with full refunds for fraudulent transactions within the first 72 hours[124]. - Rhode Island SB 16 mandates daily transaction limits of $2,000 for new customers and $5,000 for existing customers, with full refunds for fraudulent transactions within the first 30 days[125][126]. - Vermont H.137 establishes a fee cap of the greater of $5 or 15% and daily transaction limits of $2,000 for new customers and $5,000 for existing customers, with full refunds for fraud reported within 90 days[127][128]. Competition and Market Dynamics - The company faces competition from traditional financial institutions, fintech companies, and digital payment firms[481]. - The company anticipates that competition will intensify as new entrants and existing competitors enhance their offerings[481]. - The digital financial system is characterized by healthy competition and rapid innovation, with new products frequently introduced[479]. - The adoption of cryptocurrency is expected to grow, expanding the company's addressable market[477]. - The company must continue to offer competitive features and functionalities to stay relevant in the evolving market[481]. Operational Insights - The company has a significant reliance on Circle K, which represented approximately 18% and 23% of total revenues for the years ended December 31, 2025 and 2024, respectively[76]. - The company has a sophisticated Bitcoin management process, maintaining a balance of less than $1.0 million in hot wallets to manage volatility[54]. - The company typically holds less than $2.0 million in Bitcoin in its hot wallets to fulfill user orders while replenishing through liquidity providers[88]. - The company has lease commitments to acquire all kiosks for a bargain purchase option at the end of the lease term as of December 31, 2025[84]. - As of December 31, 2025, the company employed 135 full-time employees, with no labor union representation[89]. - The company is exposed to currency fluctuations, but transaction gains and losses were insignificant for the years ended December 31, 2024, and 2025[475]. - The cost of new kiosks may be significantly higher due to inflation, supply constraints, and labor shortages[478].

Revenue and Expenses - Fourth quarter 2025 revenue was $10,000, a decrease from $24,000 in the fourth quarter of 2024, while full year 2025 revenue totaled $81,000, up from $77,000 in 2024[9][13] - Total operating expenses for Q4 2025 were $9.0 million, down from $9.4 million in Q4 2024, and full year operating expenses were $36.6 million, slightly lower than $36.7 million in 2024[9][13] - Research and development expenses for Q4 2025 were $3.2 million, compared to $3.1 million in Q4 2024, while full year R&D expenses decreased to $13.2 million from $14.7 million in 2024[9][13] - Selling, general and administrative expenses for Q4 2025 were $5.7 million, down from $6.3 million in the prior year, and full year SG&A expenses increased to $23.3 million from $21.9 million in 2024[10][14] - The net loss for Q4 2025 was $7.9 million, an improvement from $8.6 million in Q4 2024, while the full year net loss was $31.9 million, down from $32.9 million in 2024[12][15] Funding and Cash Position - The company completed a public offering in February 2025, generating approximately $57.5 million in gross proceeds, extending its cash runway through 2028[4] - As of December 31, 2025, the company had cash, cash equivalents, and available-for-sale securities of approximately $95.8 million, expected to fund operations through significant adoption and commercial milestones[15] - Cash and cash equivalents slightly decreased to $3.944 billion in 2025 from $4.043 billion in 2024, a decline of about 2.5%[28] Leadership and Growth - The company appointed new leadership, including Dr. Tiffany Inglis as Chief Medical Officer and Lee Anderson as Chief Commercial Officer, to support its next phase of growth[11] - Sera expanded its commercial engagement across 13 states, with advanced discussions with 10 commercial and Medicaid payers for the adoption of the PreTRM program[5] Assets and Liabilities - Total assets increased to $101.933 billion in 2025 from $72.575 billion in 2024, representing an increase of approximately 40.5%[28] - Current assets decreased to $40.770 billion in 2025 from $47.600 billion in 2024, a decline of about 14.5%[28] - Long-term marketable securities surged to $56.579 billion in 2025, up from $21.973 billion in 2024, marking an increase of approximately 157.5%[28] - Total liabilities rose to $26.525 billion in 2025 compared to $24.772 billion in 2024, an increase of about 7.1%[28] - Stockholders' equity increased significantly to $75.408 billion in 2025 from $47.803 billion in 2024, reflecting a growth of approximately 57.9%[28] - Accumulated deficit widened to $(311.722) billion in 2025 from $(279.794) billion in 2024, indicating an increase of about 11.4%[28] - Accounts payable decreased to $862 million in 2025 from $1.969 billion in 2024, a reduction of approximately 56.3%[28] - Deferred revenue remained relatively stable at $20.315 billion in 2025 compared to $20.223 billion in 2024, showing a slight increase of about 0.5%[28] - Additional paid-in capital increased to $386.864 billion in 2025 from $327.534 billion in 2024, representing a growth of approximately 18%[28] Clinical and Market Developments - The PRIME Study published in January 2026 demonstrated that the PreTRM® Test reduced preterm births by 56% and 32% for births before 32 and 35 weeks, respectively, and resulted in a 20% reduction in NICU admissions[5]

Currency and Market Risks - The company is exposed to fluctuations in currency exchange rates, which could negatively affect operating results, particularly if the U.S. dollar strengthens, increasing costs for international customers [167]. - A significant portion of operating revenues and expenses is incurred outside the U.S., making them subject to foreign currency fluctuations, which could adversely affect financial performance [167]. - The company has not engaged in hedging foreign currency transactions, increasing vulnerability to adverse financial impacts from currency fluctuations [168]. - A strengthening or weakening of the U.S. dollar against other currencies may negatively or positively affect the company's operating results [340]. - The company is exposed to market risks primarily due to fluctuations in foreign currency exchange and interest rates [337]. Legal and Regulatory Risks - Legal and regulatory risks related to data protection and privacy laws could result in substantial costs and liabilities, potentially impacting sales of software [173]. - The company is subject to various laws and regulations, including the GDPR, which imposes strict obligations on data protection and could lead to fines up to €20 million or 4% of global turnover for non-compliance [175]. - Ongoing legal proceedings and litigation could result in significant liabilities and increased costs, potentially diverting resources from core business activities [178]. - Compliance with evolving privacy and data protection laws may require changes to business practices, potentially increasing operational costs [175]. - Future legal developments regarding data transfer regulations may require modifications to operational practices, potentially incurring greater costs [177]. - Compliance with legal and regulatory requirements in various countries is crucial; failure to meet these could result in significant liabilities and loss of customers [188]. - Non-compliance with anti-corruption and anti-bribery laws could result in significant legal liabilities and harm the company's business [205]. - The use of open source software may expose the company to litigation risks and could require costly changes to proprietary products [189]. - Indemnity provisions in customer agreements could lead to substantial liabilities for intellectual property infringement and data protection violations [190]. - The company is subject to potential securities class action litigation, which could result in substantial costs and divert management's attention [208]. Intellectual Property Risks - The company relies on a combination of patents and other intellectual property protections, but there is no guarantee that these will provide competitive advantages or be upheld in litigation [183]. - The company may face challenges in protecting proprietary technology, which could impair competitive position and lead to reduced revenue [183]. - The inability to enforce intellectual property rights could lead to delays in product sales and impair functionality, negatively impacting the company's reputation [187]. - The company may incur significant costs to monitor and protect its intellectual property rights, including potential litigation expenses [185]. Financial Position and Operations - Changes in tax laws and interpretations may adversely affect the company's financial position and results of operations [192]. - The company may face increased scrutiny and potential penalties related to its tax positions and transfer pricing in various jurisdictions [193]. - The implementation of new critical systems may disrupt operations and affect internal reporting processes [200]. - The company had cash, cash equivalents, restricted cash, and investments totaling $1.1 billion as of January 31, 2026 [338]. - A hypothetical 100 basis point increase in interest rates would result in an approximate $2.7 million decrease in the fair value of the investment portfolio [338]. - The company has a secured revolving credit facility of $750.0 million, which may be increased by an additional $250.0 million [339]. Operational Risks - Unfavorable conditions in the global economy could limit the company's ability to grow and negatively affect operating results [216]. - The company may experience disruptions due to natural catastrophic events and man-made problems, impacting business operations [217]. - Anti-takeover provisions in the company's charter documents could make acquisitions more difficult and limit stockholder actions [209].

Revenue Concentration - TAT's revenues from five major customers accounted for approximately 32.6%, 29.9%, and 28.46% for the years ended December 31, 2025, 2024, and 2023, respectively [56]. - Sales to the U.S. and Israeli governments represented approximately 9.3%, 12.4%, and 8.3% of TAT's revenues for the years ended December 31, 2025, 2024, and 2023, respectively [57]. - TAT's international sales accounted for approximately 92%, 94%, and 93% of total sales for the years ended December 31, 2025, 2024, and 2023, respectively, indicating a high revenue concentration from international markets [70]. - Direct sales to the U.S. government accounted for approximately 7.7% of TAT's revenues for the year ended December 31, 2025, compared to 9.3% in 2024 and 6.6% in 2023 [189]. Supplier and Inventory Risks - TAT relies on a limited number of key suppliers, with Honeywell International Inc. being a significant supplier for APU spare parts and other components [62]. - The company is exposed to risks related to inventory management, which could lead to supply imbalances [43]. - TAT's inventory management poses significant risks, as failure to effectively manage inventory levels could lead to supply imbalances and adversely affect business operations [68]. - TAT relies on a limited number of suppliers for components, which could impact manufacturing timelines if delays occur [221]. Competition and Market Position - TAT faces competition from established companies with greater resources, which may impact its market position and financial health [48]. - TAT's competitive environment in the aerospace and defense OEM industries is characterized by intense competition, with a focus on technological innovations, price, quality, and on-time delivery [197]. - TAT's major competitors in the MRO services market include AAR Corp, Honeywell, and Lufthansa Technik, which have inherent competitive advantages such as better name recognition and access to superior technology [200]. Financial and Operational Risks - TAT's backlog of projects is subject to unexpected adjustments, delays in payments, and cancellations, which could affect financial results [43]. - The company may engage in future acquisitions that could dilute shareholders' equity and impact business operations [43]. - TAT's operations may be adversely affected by changes in government trade policies and international trade disputes [65]. - TAT may face increased labor and raw materials costs, which could adversely affect operating profits and margins, particularly if inflationary pressures persist [66]. - TAT's financial statements are affected by fluctuations in the exchange rate between the NIS and the U.S. dollar, which can impact profitability and period-to-period comparisons [90]. - TAT's operations may be adversely affected by military service obligations of its personnel, with many employees currently serving in the IDF due to ongoing conflicts [103]. - The current war and hostilities in Israel have made it difficult to predict the economic implications on TAT's business and operations [99]. - TAT is restricted from marketing its products to certain countries, which may adversely impact operations and financial results [100]. - The Israeli government's proposed judicial reforms could potentially affect the macroeconomic conditions in which TAT operates [101]. - TAT's share price may be depressed due to Israeli corporate law regulations that complicate acquisitions and changes of control [105]. - The company has a history of volatility in its share price, which may lead to potential securities litigation in the future [93]. - TAT's registered offices are located in Israel, and its operations are subject to local political and economic conditions that could materially affect business [95]. Strategic Initiatives and R&D - TAT's future success depends on its ability to develop new offerings and technologies [41]. - TAT aims to enhance its OEM capabilities by expanding offerings to new aircraft platforms, including electrification and eVTOL [154]. - TAT established a new R&D lab, FutureWorks, in Charlotte, North Carolina, to develop next-generation thermal management systems for eVTOL aircraft, addressing challenges in cooling performance, weight reduction, and compact design [215]. - The R&D lab features advanced testing and simulation infrastructure, focusing on performance optimization, reliability, and durability of thermal management systems [216]. - TAT's strategic vision emphasizes collaboration with customers and industry stakeholders to co-develop tailored solutions that meet specific operational and environmental constraints [217]. - The company aims to exceed customer expectations by delivering future-ready thermal management systems that set new industry benchmarks [220]. Subsidiaries and Services - Limco, a subsidiary of TAT, provides MRO services for heat transfer components and is certified by FAA, EASA, and the Civil Aviation Administration of China [137]. - Turbochrome, another subsidiary, specializes in MRO services for jet engine components and provides coating powders and masking materials to OEMs [148]. - TAT's subsidiaries operate FAA- and EASA-certified repair stations, ensuring compliance with industry standards for MRO services [142]. - TAT's MRO contracts with customers are generally long-term engagements, with terms ranging from one to ten years or more [144]. - Piedmont provides MRO services for APUs and landing gear, with a focus on comprehensive repair and overhaul services for Honeywell APU models [177]. - Turbochrome plans to expand its MRO operations by developing capabilities for additional types of jet engine components with significant commercial potential [182]. Compliance and Regulatory Environment - The aerospace industry is highly regulated, and TAT may incur significant fines and penalties if it fails to comply with regulations [47]. - TAT's operations are subject to various environmental laws and regulations, and non-compliance could result in significant liabilities and operational limitations [83]. - The company is subject to extensive aerospace regulations and believes it meets or exceeds FAA maintenance standards in its repair and overhaul activities [230][231]. - TAT's operations in Israel are certified by the Israeli Ministry of Defense and the Civil Aviation Administration, requiring export permits for certain products [234]. Engineering and Innovation - TAT's engineering capabilities are a strategic core competency, enabling the company to meet complex customer demands while maintaining efficient development cycles [209]. - TAT is focused on enhancing its engineering capabilities and investing in new technologies to strengthen its market position and enter more advanced platforms [208]. - TAT estimates the market size for Turbochrome's MRO services to be significant, based on the number of jet engines requiring these services [182]. - The demand for MRO services is driven by the aging aircraft fleet and increased maintenance costs, leading carriers to seek reliable third-party providers [164][175].

Clinical Trials and Development - Annamycin is currently in a pivotal Phase 3 trial (MIRACLE trial) for relapsed/refractory acute myeloid leukemia (AML), with interim unblinding expected in mid-2026[21]. - The company has completed a total of eighteen clinical trials across its three core portfolios, with ongoing and planned trials for Annamycin and other drug candidates[22][32]. - The MIRACLE trial has shown promising blinded safety and efficacy data for the first 30 subjects treated, with further data expected for the first 45 subjects[25]. - The company is planning a Phase 1B/2 trial for Annamycin as a monotherapy for third-line pancreatic cancer, expected to begin in 2026[32]. - The Phase 1B/2 trial for Annamycin in STS lung metastases (MB-107) reported a median overall survival (OS) of 13.5 months[1]. - The Phase 1 clinical trial for pediatric brain tumors with WP1066 concluded with positive results, including partial tumor response in a DIPG patient[46]. - The MB-106 trial included 23 subjects recruited on an Intent-To-Treat (ITT) basis, with 22 subjects safety evaluable[39]. - The interim unblinding of the MIRACLE trial is expected to occur in mid-2026, with the first 45 subjects treated[43]. - The amended protocol allows for an interim unblinding of data for the first 45 subjects treated across three arms of the trial[43]. - The final clinical study report (CSR) for the MB-106 trial is expected to be published in late March 2026[90]. - The FDA approved the design of a Phase 2B/3 pivotal trial for AML patients who are refractory or relapsed after induction therapy, with a focus on complete remission as the primary endpoint[92]. - The MIRACLE trial will include 222 subjects in Part B, randomized to receive either HiDAC plus placebo or HiDAC plus the optimum dose of Annamycin[100]. - The preliminary composite complete remission rate in the MIRACLE trial's first 30 subjects was reported at 40%, outperforming historical outcomes for cytarabine alone[98]. - The Phase 1B portion of the MB-106 trial has successfully completed recruitment, with a focus on both first-line and second-line therapy subjects[89]. Drug Efficacy and Safety - Annamycin has demonstrated a complete remission (CR) rate of 50% and a composite CR rate of 60% in combination with Cytarabine for R/R AML as second-line therapy[25]. - Annamycin is designed to be non-cardiotoxic, with some patients safely dosed at five times the typical lifetime maximum allowable anthracycline dose[25]. - The FDA's feedback indicated no cardiotoxicity in previous trials, supporting the continuation of Annamycin's clinical development[40]. - Clinical trials have shown no evidence of cardiotoxicity in over 100 subjects treated with Annamycin, including 90 subjects across five trials, with one subject receiving a cumulative dose of 3420 mg/m2 without cardiotoxic effects[59]. - Annamycin has shown a 100% survival rate in a preclinical study for metastatic osteosarcoma, compared to only 10% for untreated animals, indicating its potential therapeutic benefits[68]. - Annamycin has shown no signs of drug-related cardiotoxicity, allowing for higher dosing and potential treatment of traditionally "Unfit" patients[75]. - In the MB-106 trial, 36% of all subjects achieved a complete response (CR), with a median overall survival (OS) of 15.2 months for CR responders[86]. - Annamycin's unique multilamellar lipid-based delivery system is designed to improve bioavailability and increase the therapeutic window[24]. - Annamycin's unique multilamellar lipid delivery mechanism enhances its pharmacokinetics, resulting in improved tissue distribution and retention compared to existing anthracyclines[51]. - The drug demonstrates a significant ability to overcome multidrug resistance, potentially allowing for higher drug uptake in diseased cells and more effective treatment outcomes[61]. Market and Competitive Landscape - Approximately 150,000 people are living with AML worldwide, with over 20,000 new diagnoses annually in the U.S.[69]. - An estimated 60% of AML patients have a significant unmet need for new therapies, as only about 40% can achieve a curative bone marrow transplant or lasting remission[69]. - The 5-year survival rate for AML is roughly 30%[69]. - Only about 36% of "Fit" patients achieve a durable complete response (CR) from the standard "7+3" therapy, translating to approximately 14% of all AML patients[71]. - For "Unfit" patients treated with "Ven-Aza," the success rate is around 37%, leading to about 15% of all AML patients achieving a positive outcome[72]. - Six new targeted therapies have been approved for 2nd line patients, but only about 21% of these patients achieve a durable CR, affecting an additional 18% of the AML population[74]. - The global market for anthracyclines, including the lead drug candidate Annamycin, was estimated at $1.3 billion in 2023 and is projected to grow to $2 billion by 2032[176]. - The market for soft tissue sarcoma (STS) is estimated to be $1.58 billion in 2024, with expectations to grow to $2.57 billion by 2030[180]. - An estimated 67,440 new cases of pancreatic cancer will be diagnosed in the US in 2025, with a mortality rate of 51,980[182]. - The oncology drug market has seen checkpoint inhibitors generate over $10 billion in annual revenues, but they are ineffective in certain "non-responsive" tumors, prompting a focus on combination therapies[114][115]. Regulatory and Developmental Designations - The company has obtained patent protection for Annamycin through 2040, with potential extensions to 2045, along with Orphan Drug and Fast Track designations[27]. - Annamycin has received Orphan Drug Designation from the FDA and EMA for the treatment of AML and soft tissue sarcoma, indicating a medically plausible basis for its use[50]. - The FDA has granted Fast Track Designation for Annamycin, allowing for expedited development and review processes[50]. - The WP1066 Portfolio Program has received FDA orphan drug designation for glioblastoma treatment, indicating a medically plausible basis for its use[111]. - The FDA granted WP1066 a "Rare Pediatric Disease" designation, which may provide a Priority Review Voucher valued at up to $100 million upon approval[186]. Company Operations and Financials - The company has a workforce of 17 employees as of year-end 2025, operating primarily in a virtual environment without manufacturing facilities[146]. - The company relies on third-party contract manufacturers for all aspects of API manufacturing and drug product formulation[149]. - Total expenses under license agreements with MD Anderson were $0.2 million and $0.3 million for the years ended December 31, 2025 and 2024, respectively[168]. - The company has a sponsored research agreement with MD Anderson running until March 31, 2027, with expenses of $2.0 million and $0.8 million for the years ended December 31, 2025 and 2024, respectively[170]. - The company has sublicensed certain intellectual property rights to Animal Life Sciences, requiring commercialization efforts for non-human uses of Annamycin by 2028[171]. - The ALI Agreement requires ALI to pay a royalty of 5.0% on net sales of sublicensed products, in addition to the royalty owed to MD Anderson[172]. Future Projections and Trends - The US is expected to see 2.0 million new cancer cases and 618,120 cancer deaths in 2025, translating to approximately 1,693 deaths per day[174]. - There are 551 ongoing clinical trials for pancreatic cancer, indicating significant competition and development activity in this area[200]. - The FDA requires extensive preclinical data and compliance with Good Laboratory Practice (GLP) before human clinical trials can begin[206]. - Clinical trials are conducted in three phases, with Phase 1 focusing on safety and dosage, Phase 2 on effectiveness, and Phase 3 on risk/benefit analysis[210]. - The NDA submission process includes substantial fees and must demonstrate safety and effectiveness across all relevant pediatric subpopulations[215]. - The FDA aims to complete NDA reviews within 12 months, but this can be extended for additional information requests[216]. - The FDA has programs to expedite drug development for serious conditions, but eligibility can change based on specific product candidate circumstances[217]. - Priority Review aims to complete NDA review within eight months of submission[219]. - Accelerated Approval allows for approval based on surrogate endpoints that predict clinical benefit[219]. - Fast Track enables rolling review of NDA sections before complete application submission[219]. - Breakthrough Therapy provides for expedited review and rolling review of NDA[219].

Financial Performance - The company reported an operating loss of $13.99 million for the year ended December 31, 2025, compared to a loss of $12.05 million in 2024, reflecting an increase in operating expenses [360]. - The accumulated deficit reached approximately $100.8 million as of December 31, 2025, with a net loss of about $13.56 million for the year [372]. - The company had no revenue for the years ended December 31, 2025 and 2024, with no immediate sales prospects [361]. Research and Development - Research and development costs increased to $7.81 million in 2025 from $7.27 million in 2024, primarily due to ongoing testing and related expenses for the Phase 1B trial for NGC-Cap [364]. - The company anticipates future increases in research and development costs as it finalizes clinical trials and expands its development team [365]. - The company anticipates ongoing negative cash flows from operating activities due to continued research and development efforts [377]. Expenses - General and administrative expenses rose to $6.18 million in 2025, up from $4.78 million in 2024, driven by increases in salaries, stock-based compensation, and professional fees [368]. - Net cash used in operating activities increased to $11,385,195 in 2025 from $11,245,042 in 2024, primarily due to higher costs related to the Phase 2 trial for NGC-Cap and increased payroll expenses [377]. - As of December 31, 2025, prepaid expenses included $1.0 million for advanced payments related to Phase 1B and Phase 2 trials of NGC-Cap [378]. Cash and Financing - Cash and cash equivalents stood at $5.5 million as of December 31, 2025, following a net cash increase of $4.35 million during the year [371]. - The company plans to raise additional capital in the second quarter of 2026 to support ongoing research and development activities [372]. - Net proceeds from financing activities in 2025 totaled approximately $10.6 million from the sale of common stock and warrants [380]. - In 2024, net proceeds from financing activities amounted to $6.3 million from the sale of common stock in a public offering [381]. - The company has filed a registration statement for an at-the-market offering of up to $50 million, with an initial offering price of up to $5.2 million [359]. Digital Assets - The company recorded $295,180 in unrealized gains on digital assets and $109,491 in interest income for the year ended December 31, 2025 [369]. - The company used $850,000 in investing activities to purchase digital assets in 2025 [379]. - Digital assets are measured at fair value, with significant volatility and liquidity considerations impacting valuation [395]. Contracts and Obligations - The company has entered into contracts with CROs and clinical supply manufacturers, which are generally cancelable and not included in contractual obligations [382]. - No off-balance sheet arrangements were reported during the periods presented [384]. Tax Considerations - The company recorded a valuation allowance for deferred tax assets, as it is more likely than not that benefits will not be realized [393].